Highlights
- 1
- 2European journal of nuclear medicine and molecular imaging · 2025
- 3Translational oncology · 2022
Publications
153 publications
Funding
17 grantsView NIH portfolio on RePORTER ↗
Active
8 grants- Co-IESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancerNational Cancer Institute · 2024–2029
- Co-IWhole-Body MRI Assessment of Body Composition Remodeling During GLP-1 Agonist Therapy for ObesityRadiological Society of North America · 2026–2028RSNA 260380-01
- Co-IOptimization of Prostate-Specific Membrane Antigen-Targeted RadiationProstate Cancer Foundation · 2017–202717CHAL11
- KPModernization and Expansion of the Citigroup Biomedical Imaging Center at Weill Cornell Medical CollegeOffice of the Director, NIH · 2023–2027C06OD036045-01
- Co-IDevelopment and optimization of CEACAM5-targeted alpha emittersProstate Cancer Foundation · 2025–202724CHAL11
- Co-IHeating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumabU.S. Department of Defense · 2020–2026W81XWH-20-1-0706
- Co-IComprehensive Assessment of Cancer Theranostics ResponseNational Cancer Institute · 2023–2026 · via AIQ Global, Inc.R44CA285006-01
- KPNew PET/CT System for Human and Non-human Primate ImagingOffice of the Director, NIH · 2023–2026S10OD034271-01
Completed grants (9)
- Co-IMRI Detection of CarotId Plaques as a mecHanism for Embolic strokes of undeteRmined source (MRI DECIPHER)National Heart, Lung, and Blood Institute · 2019–2025R01HL144541-05
- KPEvaluation of prostate specific membrane antigen (PSMA) as a radiotherapeutic target in glioblastoma multiforme (GBM)Radiological Society of North America · 2024–2024RSNA 230525-01
- Co-IUnderstanding the dynamic interactions between tau pathology and microgliamediated inflammation in Alzheimer's DiseaseNational Institute on Aging · 2021–2024
- MPI124I-NaI PET: Building block for precision medicine in metastatic thyroid cancerNational Cancer Institute · 2019–2021 · via Memorial Sloan Kettering Cancer CenterR01CA201250-05
- PIA new technique to make 68Ga-labeled pharmaceuticals widely available for clinical useNational Cancer Institute · 2018–2021R01CA207645-03
- KPImaging Neuroinflammation in Alzheimer's Disease (AD) with [11C] Arachidonic Acid and PETNational Institute on Aging · 2009–2013
- PIImmunoPET Based on Anti-PSMA Antibody, 89Zr-J591 for Molecular Imaging of Prostate CancerNational Cancer Institute · 2011–2012
- KPQuestionable Dementia II: Course and Predictors of OutcomeNational Institute on Aging · 2010–2011
Clinical research
7 studies
Active
2 studies- PINCT04886986Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate CancerPHASE1 · Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2026)Prostate Cancer
- PIWCM catchment Prostate Cancer Health Impact Program (pCHIP) 2Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
Completed & closed trials (5)
- PINCT07052214A Single Arm, Multicenter, Prospective, Open Label, Longitudinal Phase 3 Study of Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) Combined With Magnetic Resonance Imaging (MRI) Compared to Standard of Care (SOC) for the Detection of Prostate Cancer (PCa).PHASE3 · Telix Pharmaceuticals (Innovations) Pty Ltd. · CLOSED TO ACCRUAL (as of 2026)PCA; Prostate Cancer; Prostatic Neoplasm; PSMA PET; Diagnostic Imaging; Elevated PSA; Positron Emission Tomography; Prostate Biopsy; Carcinoma of the Prostate
- PINCT04506567Phase I/II Dose-escalation Study of Fractionated and Multiple Dose 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate CancerPHASE1 · Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)Prostate Cancer
- PINCT05413850An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate CancerPHASE1; PHASE2 · Blue Earth Therapeutics Limited · CLOSED TO ACCRUAL (as of 2025)Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; mCRPC; Urogenital Neoplasms; Prostatic Neoplasms; Prostatic Diseases
- PINCT04293406WCM Catchment Prostate Cancer Health Impact Program (pCHIP)Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2024)Prostate Cancer
- PINCT04685811Evaluation of a 68Ga Small Molecule PSMA Antagonist Produced by Two Different MethodsPHASE1; PHASE2 · Weill Medical College of Cornell University · IRB STUDY CLOSURE (as of 2022)Metastatic Prostate Adenocarcinoma
Mentoring
4 menteesAll publications with mentees →
- ZBZodina BeieneMD mentee · Class of 2018
- KAKwabena AmankwahMD mentee · Class of 2023
- YGYendé GrellMD mentee · Class of 2022
External relationships
Advisory/Scientific Board Member
Telix Pharmaceuticals (Innovations) Pty Ltd.
Other
Siemens Medical Solutions USA INC · Telix Pharmaceuticals (Innovations) Pty Ltd.